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LPAR2 REGULATES LPA-INDUCED OSTEOCLAST SEALING ZONE DYNAMICS 
Stephanie M. Meyer 
Abstract 
Bone metastasis is an excruciating consequence of multiple primary cancers, and is 
commonly treated with bisphosphonate drugs. Osteoclasts, bone-resorbing cells vital to proper 
bone remodeling and fracture healing, are responsible for the formation of osteolytic bone 
tumors. Osteoclasts function through an actin-based structure called the actin sealing zone, or 
actin ring. Actin ring formation is required for proper bone resorption, and can be used to 
measure osteoclast function.  
The Lee lab is investigating the mechanisms of lysophosphatidic acid (LPA) treatment on 
osteoclasts. LPA is a lipid molecule found at elevated levels in the blood of cancer patients. In 
preliminary in vitro experiments, osteoclasts were directly treated with LPA.  Cells were also 
exposed to LPA in the presence of a common bisphosphonate, Zometa, which is currently used 
to treat the osteoporosis commonly observed in cancer patients.  In the absence of Zometa, LPA 
increases the actin ring circumference and the number of cellular nuclei.  Zometa treatment 
decreases the actin ring perimeter and number of nuclei. Osteoclasts treated with Zometa and 
LPA simultaneously show an expanded actin ring and elevated number of nuclei, similar to the 
phenotype induced by exposure to LPA alone.  Cells treated with Zometa after LPA exposure 
showed no observable response to the drug.  
LPA works through five known receptors, three of which are defined in osteoclasts. The 
LPA receptor (LPAR) 1/3 inhibitor Ki16425 did not suppress the actin ring increase by LPA. 
However, LPAR2 agonist FAP12 demonstrated effects identical to those observed in the 
presence of LPA on bone. Such data suggests that LPAR2 is responsible for the actin ring 
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perimeter and nuclear quantity changes seen with LPA treatment.  Small interfering RNAs 
(siRNAs) specific to LPAR2 were utilized to examine LPAR2 function.  Knockdown of LPAR2 
inhibited the actin ring expansion observed in cells with functional LPAR2. The results suggest 
that LPAR2 is a key element in LPA-induced actin sealing zone dynamics, and is consequently a 
new target for alternative drug therapies to treat LPA-induced bone metastasis. 
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1.  Introduction 
Bone remodeling occurs continuously throughout an individual’s lifetime, and it is 
critical to bone growth, fracture healing, and homeostasis of blood calcium and phosphate levels. 
Approximately 10% of the bone mass of an adult human is replaced annually, equating to 
turnover of the entire skeleton in the span of one decade (Alliston 2002).  During bone 
remodeling osteoclasts degrade bone, while osteoblasts replenish the degenerate bone structure. 
Pathologies such as osteoporosis (deficient bone mass) and osteopetrosis (abnormally dense bone 
mass) result if the activity of both cell types is not in equilibrium (McMichael 2008).  
Osteoclasts are multinucleated cells, measuring up to 100 microns in diameter and containing an 
average of 4 to 20 nuclei within the cell body (McMichael 2008).  RANKL (Receptor Activator 
for Nuclear Factor κ B Ligand) is secreted by osteoblasts in the bone environment, and is mainly 
responsible for stimulating osteoclast differentiation through the activation of multiple signaling 
cascades (Teitelbaum 2007).  Critical to the resorption function, osteoclasts form F-actin ring-
like structures, referred to as “sealing zones” (Teitelbaum 2007). 
Formation of an F-actin sealing zone, or actin ring, is critical to the bone resorption 
process (Saltel 2004).  The resorption process can be divided into three stages: adhesion of the 
osteoclasts to the bone surface, resorption of the bone matrix, and migration of the osteoclast 
(Saltel 2004).  The actin sealing zone anchors the osteoclast to the bone surface via integrins, 
most notably αvß3 (Saltel 2004).  Other labs have concluded that osteoclasts “can only resorb 
mineralized matrices,” as resorption has not been seen to occur on demineralized bone (Saltel 
2004).    After the osteoclast is anchored to the bone surface, the cell becomes polarized and 
forms an “actin patch” structure, which is thought to develop into the actin sealing zone (Lee 
1999).  A signaling cascade releases proteolytic substances, such as hydrochloric acid and 
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Cathepsin K (CatK), into the bone microstructure (Zou 2010).  Following resorption, the 
osteoclast “spreads,” describing a depolarized state in which the cell does not have an actin ring 
structure  (Saltel 2004).  During this spreading state, the osteoclast migrates to a new location on 
the bone surface, creating a resorption pattern thought to be determined by certain glycoproteins 
on the bone surface (Saltel 2004).  A new actin ring is formed as the cell polarizes, repeating the 
cycle as indicated in Figure 1a.  
Bone is the most common site of secondary metastasis in breast cancer patients, 
suggesting that the biochemical ramifications of cancer may affect the cells responsible for 
maintenance of the bone matrix (Pavlakis 2006).  Previous studies have implicated 
lysophosphatidic acid (LPA, Figure 1d) as a key signaling molecule involved in cancer cell 
proliferation. LPA is a phospholipid signaling molecule that is speculated to incite the secondary 
metastasis of breast cancer to bone (Boucharaba 2006).  For example, elevated LPA levels have 
been observed in the blood of breast cancer patients (Nogouchi 2009).  Thus far, five LPA cell 
receptors have been characterized, and at least three are present in osteoclasts (Nogouchi 2009, 
Lapierre 2008).  While research has been done to examine the LPA-induced activation of breast 
cancer cells, as well as the inhibition of cancer cell apoptosis by LPA, the effect of aberrantly 
high LPA levels on osteoclasts has not been well-characterized (Nogouchi 2009).   
  Since bone metastasis accounts for thirty to forty percent of all recurrences of primary 
breast cancer, several therapeutic approaches have been employed to prevent the spread of 
malignant cells to secondary sites throughout the body (Suva 2010).  One clinical treatment is the 
use of bisphosphonate drugs, such as Zometa (zoledronic acid).  Zometa is a common 
bisphosphonate prescribed to prevent bone complications following primary cancers (Gnant 
2009).  Bisphosphonate drugs inhibit bone matrix degradation via induction of osteoclast 
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apoptosis, or programmed cell death (Figure 1c) (Beauchamp 2002).  Bisphosphonates are also 
currently used to treat non-cancerous bone abnormalities.  Examples include pediatric 
osteogenesis imperfecta, a condition in which osteoblasts do not produce sufficient bone matrix 
to replace the minerals resorbed by osteoclasts, and osteoporosis, in which osteoclasts resorb 
more bone matrix than is replaced by the osteoblasts (Lindsay 2002).  One study suggests that 
bisphosphonates biochemically inhibit LPA from inducing migration of human ovarian cancer 
cells (Sawada 2002). Another research group has suggested that Zometa has anti-cancer 
progression effects (Gnant 2009).  However, while such studies assume bisphosphonates’ ability 
to simply inactivate the osteoclast, the effect of LPA on bisphosphonates’ activity in the context 
of osteoclast bone resorption remains uninvestigated (Gnant 2009).  The following project 
examines the effects of LPA on osteoclasts, as well as LPA’s effect on the interactions of 
bisphosphonates with the osteoclasts themselves.  
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2.   Methods 
2.1  Preparation of Osteoclasts 
Primary cells were generated by extracting monocytes from mouse bone marrow, 
maturing them into macrophages with M-CSF (Macrophage Colony Stimulating Factor), and 
differentiating the cells into adult osteoclasts upon addition of RANKL.  RANKL, or Receptor 
Activator for Nuclear Factor κ B Ligand, is a molecule naturally present on osteoblasts that 
incites activation of osteoclasts.  Thin slices of ivory were stored in PBS (phosphate-buffered 
saline), soaked in cell culture media, and placed into the wells of a sterile plate.  Mature 
macrophages were quantified and diluted with PBS to get the recommended concentration of 
cells (approximately 1 x 105 cells /6-well plate, detected using hemacytometry).  Dulbecco’s 
Modified Eagle Medium (DMEM, 3 mL) and RANKL (2 μL) were also added to each well, and 
cultures were incubated for 48 hours at 37°C  (Krits 2002) 
 
2.2  Fixation of Osteoclasts 
After cells were treated under various conditions (addition of LPA, Zometa, Ki16425 
inhibitor, FAP12), the cultures were quickly fixed in 1% formaldehyde and then additionally 
fixed in 2% formaldehyde.  Cells were stained using standard methods for either Phalloidin or 
LPAR2-specific primary antibodies followed by fluorescent secondary antibodies. The slides 
were viewed under the Zeiss Meta Confocal microscope or a Nikon Epifluorescence microscope, 
and the actin sealing zone perimeters were measured using Sigma Scan Pro 5.0.  Averages and 
standard deviations were calculated and compared (Zeng 2000). 
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2.3  Bone Assays 
Differentiated RAW 264.7 osteoclasts were plated on BD-osteological discs or ivory for 
three days, while being treated with either vehicle control or LPA/FAP12. Cells were removed 
and viewed under low magnification with the Nikon epifluorescence microscope.  For MBM 
primary assays, mature osteoclasts were plated on ivory and treated for three days with vehicle or 
LPA/FAP12. Cells were removed, and the remaining pits were stained with acid hematoxylin to 
be viewed with the Zeiss Meta Confocal microscope.   
 
2.4  siRNA Suppression of LPAR2 Gene 
siRNAs (75071, 74987, 74894) were purchased from Ambion and transfected using 
Lipofectamine 2000 from Invitrogen.  Cells were differentiated four days before control or 
LPAR2-specific siRNAs were added to Lipofectamine 2000. For bone assays, immediately 
following the transfection, cells were scraped and re-plated on ivory.  RNA or protein was 
harvested two days post-transfection. Competitive RT-PCR was utilized to analyze the decrease 
in RNA.  An internal standard was created that contained the same primer-binding sequence as 
LPAR2, but lacked approximately 20% of the internal sequence.  300 fg of internal standard was 
added to 1 µg of sample prior to reverse transcriptase, and then subject to standard PCR 
conditions.  Western analysis was used to analyze protein following standard lab protocols (Zeng 
2000). 
 
2.5  Reagents 
Lysophosphatidic acid (LPA) was used at a 2 µM concentration and ordered from the 
Cayman Chemical Company.  Zometa (zoledronic acid), provided by Dr. Thomas Rosol of The 
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Ohio State University College of Veterinary Medicine, was used at a concentration of 3.75 
ng/mL.   Ki16425 inhibitor was used at 10 µM, and obtained from the Cayman Chemical 
Company.  FAP12, ordered from BioMol, was used at a concentration of 50µM.  Control and 
LPAR2-specific siRNAs (75071, 74987, 74894) were acquired from Ambion and were used at a 
75 nM concentration, and rabbit polyclonal LPAR2-specific antibodies were ordered from 
Abcam.  Bisbenzamide was purchased from Sigma Aldrich, and both Phalloidin and 
Lipofectamine 2000 were purchased from Invitrogen. 
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3. Results 
The Effects of LPA and Zometa on Actin Sealing Zone Perimeter and Nuclear Number 
A search through previous data indicates that there are currently no published papers in 
which LPA was directly added to osteoclasts. I began my studies by assessing the initial changes 
seen in osteoclasts by the addition of LPA alone and LPA in the presence of Zometa. 
 
3.1  LPA Increases Osteoclast Sealing Zone Perimeter, Nuclear Number and Resorption 
Osteoclasts derived from both an immortalized cell line (RAW 264.7 cells), as well as 
fresh cells derived from mouse bone marrow (MBM cells) were plated in wells that contained 
four to six bone slices.  LPA (2 μM) was added to one well, and the other well was left untreated 
as the vehicle control.  The cultures were incubated at 37°C for 24 hours, and then the bone 
slices were fixed and stained with fluorescent Phalloidin and bisbenzamide to view the actin 
sealing structures and nuclei.   
Data indicates that LPA increases sealing zone perimeter, relative to osteoclasts 
unexposed to LPA (Figure 2a).  Both RAW 264.7 cells and MBM primary cells exhibited 
sealing zones with perimeters approximately double the size of the control (Figure 2b).  Also, 
nuclear number increased in both subsets of cells following LPA treatment (Figure 2c).  Larger 
osteoclasts, deemed as such by a greater number of nuclei, are more likely to be in an active state 
of resorption (Lees 2001).  This data indicates that LPA has a direct effect on osteoclasts.   
Differentiated osteoclasts were also plated on either BD-osteological discs or ivory.  
RAW 264.7 cells were treated with either vehicle solution alone or LPA, and cultured on 
osteological discs at 37°C for three days.  Cells were then removed and the clearings quantified. 
Additionally, MBM primary cells were subject to the same conditions, on ivory medium.  After 
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removing cells from the culture surfaces and staining resorbed zones with hematoxylin, the pits 
were quantitatively characterized.  On the synthetic osteological disks, LPA increased the 
resorption area and the total percentage of the bone surface resorbed, relative to a 100% 
resorption control (Figure 2d).  LPA did not significantly affect the number of resorption pits 
formed.  The MBM primary cells cultured on bone showed that LPA increased the areas of the 
individual resorption pits relative to the untreated control cell resorption zones; however, no 
change in resorption pit height was seen (Figure 2d).   
 
3.2  LPA and Zometa have Contrary Effects 
Osteoclasts were cultured on bone, as described in the “Preparation of Osteoclasts” 
protocol.  LPA was added to one well, Zometa was added to the second well, and both LPA and 
Zometa were added to the third well.  The cells were incubated at 37°C for 48 hours, and then 
fixed and stained with fluorescent Phalloidin to view the actin sealing zone.  The cells were 
viewed using confocal microscopy and the actin rings measured.   The nuclei of cells with actin 
rings were also stained with bisbenzamide and quantified.   
Figure 3a shows that while LPA increased the perimeter of the actin sealing zone, 
Zometa decreased the sealing zone perimeter.  However, when osteoclasts were exposed to both 
LPA and Zometa simultaneously, the sealing zone perimeter increased, measuring comparably to 
the sealing zone size of osteoclasts exposed only to LPA (Figure 3b). The nuclear number data 
revealed a similar pattern (Figure 3c).  Such data implies that LPA may interfere with the 
mechanism of how bisphosphonates, particularly Zometa, downregulate osteoclast resorption. 
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3.3  Pre-treatment with LPA Makes Zometa Ineffective 
To determine whether the chronological order of LPA and Zometa addition had any 
effect on the actin sealing zone or nuclei phenotypes, osteoclasts were cultured on bone for four 
days. LPA or Zometa was added to each well and incubated at 37°C for 24 hours.  After 24 
hours, LPA or Zometa was added so that one sample had two days of Zometa treatment and one 
day of LPA exposure (2D Zometa-1D LPA), and the other sample had two days of LPA 
exposure and one day of Zometa treatment (2D LPA-1D Zometa).  After a total incubation time 
of 48 hours, slides of the osteoclasts were fixed and stained with Phalloidin and bisbenzamide to 
view the osteoclasts’ actin rings.  Actin rings and nuclei were quantified. 
Exploration of the time effects of LPA and Zometa on osteoclasts revealed that when 
osteoclasts are treated with Zometa 24 hours prior to LPA exposure, the measurable actin sealing 
zones remained small, similar to untreated control cells.  However, the majority of cells did not 
have measurable actin rings after 24 hours of treatment with Zometa, as depicted in Figure 4a.  
However, if cells are subjected to LPA 24 hours before exposure to Zometa, the actin ring size 
increases as in osteoclasts exposed to LPA alone (Figure 4b).  The nuclear number data trended 
with the actin ring data (Figure 4c).  This data reveals that if a high level of LPA is present 
before Zometa is administered, then the effects of Zometa on actin sealing zone formation may 
be negated. 
 
The Molecular Mechanism of LPA Action 
Since LPA has a direct effect on osteoclasts and can override Zometa treatment, I 
continued my studies to better understand how LPA regulates osteoclasts. There are currently 
five known LPA receptors, and three are known to be present in osteoclasts. The following 
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assays were designed to elucidate the particular receptor through which LPA functions, as well 
as to determine the specific effects that result from activation of the receptor.   
 
3.4  LPA is Not Inhibited by LPAR1/3 Antagonist Ki16425 
Osteoclasts were cultured on bone and treated with either vehicle, LPA, or with Ki16425 
inhibitor in the presence of LPA.  Ki16425 is a pharmacological inhibitor that acts specifically 
blocks LPAR1 and LPAR3.  The cells were incubated for 24 hours, and stained with Phalloidin 
and bisbenzamide according to standard lab protocol.  The actin sealing zone sizes were 
measured and the nuclear number counted.   
  Even with LPAR1 and LPAR3 biochemically hindered by the Ki inhibitor, the sealing 
zone perimeter still increased (Figures 5a, b).   Ki16425 inhibitor was added at 2x and 10x 
concentration and still had no effect on actin ring expansion or nuclear number (data not shown).  
This result suggests that LPAR1 and LPAR3 are not major receptors involved in LPA’s 
mechanism for increasing the actin sealing zone perimeter.  The number of nuclei also increased 
when treated with LPA and Ki16425 inhibitor, mimicking the nuclear effects observed with LPA 
alone (Figure 5c).  Additionally, Ki16425 inhibitor was also added to cells exposed to LPA for 
two days and Zometa for one day (2D LPA- 1D Zom) as described in Results 2.3 (data not 
shown).   While doing so slightly decreased actin ring perimeter and nuclear number, the 
reduction of both osteoclast structures did not reach near normal levels.  This data implies that 
even with suppression of LPAR1 and LPAR3, LPA still interacts with the osteoclast in order to 
increase the sealing zone and nuclear number.   
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3.5  LPAR2 Agonist FAP12 Mimics LPA Effects 
Osteoclasts were treated with either LPA or FAP12.  FAP12 is an LPA agonist that acts 
specifically to simulate activation of LPAR2 by LPA.  The cells were incubated for 24 hours, 
and stained with Phalloidin and bisbenzamide to measure the actin sealing zone sizes and nuclear 
number.   
When LPA agonist FAP12 was added to osteoclasts, the same degree of actin sealing 
zone expansion resulted as when cells were treated with LPA alone (Figures 6a, b).  Nuclear 
number data shows that there is also an increase in cell fusion when osteoclasts were treated with 
FAP12, as seen in the osteoclasts treated with LPA (Figure 6c). Since FAP12 interacts 
specifically with LPAR2 and no other known LPA receptors, such data suggests that LPA’s 
interaction with LPAR2 is primarily responsible for the larger perimeter of the osteoclast’s actin 
sealing zone.   
MBM-derived osteoclasts were plated on ivory and either left untreated in vehicle 
solution, were treated with LPA, or were treated with FAP12.  The cells were incubated for 72 
hours at 37°C, removed from the ivory, and stained with acid hematoxylin to be viewed using 
epifluorescent microscopy.  Both the LPA and FAP12 treated cells exhibited an increased 
resorption pit area relative to the untreated control cells.  However, the height of the resorption 
pits remained statistically similar upon comparison of LPA/FAP12 treated cells versus the 
untreated control (Figure 6d).   
 
3.6.  siRNA Suppression of the LPAR2 Gene Diminishes LPA Effects 
Osteoclasts were stained with LPAR2-specific antibodies.  LPAR2 was found throughout 
the osteoclast, indicating that the LPAR2 protein’s location is not specific to the actin structures 
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(Figure 7a).  Three LPAR2-specific siRNAs were used to inhibit expression of the LPAR2 gene. 
Controls of LPAR2 siRNAs were transfected via lipid-based Lipofectamine 2000 on day four of 
osteoclast differentiation, and RNA (Figure 7b) or protein (Figure 7c) was harvested and 
assessed two days post-transfection.  A competitive RT-PCR confirmed that all three siRNAs 
inhibited the sample RNA expression, as the top band in Figure 7b represents the sample 
LPAR2 RNA and the bottom band is the internal standard control.  Western blot analysis showed 
that siRNA1 and siRNA2 inhibited protein expression most effectively, while the ß-actin control 
remained constant (Figure 7c).  
To further test if LPAR2 is the primary LPA receptor responsible for the LPA-induced 
actin ring changes, osteoclasts on ivory were transfected with siRNAs for either a nonsense 
control (C) or LPAR2 (Si) in both the presence and absence of LPA.   The cellular actin was 
stained with Phalloidin to view sealing zone formation.  Knock-down of LPAR2 resulted in 
smaller actin sealing zones relative to the control in the presence of LPA (Figure 8b).  Also, as 
indicated in the graph in Figure 8a, an increase in the actin ring size only occurred when a cell 
containing control siRNA, non-specific to LPAR2, was treated with LPA.  Since there was no 
significant increase in actin sealing zone size in cells containing the LPAR2-specific siRNA, this 
data confirms that the LPAR2 protein is a major receptor in osteoclasts for regulating sealing 
zone expansion.  
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4.  Discussion 
The data from the experiments provides three major conclusions.  First, LPA causes 
expansion of the actin sealing zone, as well as an increase in the number of nuclei in the cell 
body.  Second, not only does LPA cause an increase in sealing zone size, but the data suggests 
that LPA has a mechanism that negates activity of bisphosphonate drugs, specifically Zometa.  
Third, after inhibiting LPAR1 and LPAR3 with Ki16425 inhibitor, as well as using FAP12 to 
stimulate only LPAR2 and confirming the effect through LPAR-2 specific siRNA suppression, it 
is likely that LPAR2 is the primary osteoclast receptor responsible for the LPA-induced 
phenotypes of the actin sealing zone and nuclear number.  
 This is the first documented study that looks at the direct effects of LPA on mature 
osteoclasts, and the findings of this project create new avenues for both clinical and benchtop 
exploration. Knowledge of such cellular effects may have substantial implications in the clinical 
setting.  Understanding the mechanisms of LPA action may lead to determining whether or not a 
correlation exists between threshold levels of serum LPA and those breast cancer patients who 
experience secondary bone metastasis.  Also, if LPA levels become increasingly elevated as 
cancer progresses in patients, then prescribing Zometa to late-stage cancer patients may not be as 
effective as physicians are expecting.  Such information could improve treatment guidelines for 
breast cancer patients.   Zometa may be administered in early stages of the cancer, and perhaps 
preventative doses of bisphosphonate could be prescribed to those deemed high risk for 
developing the cancer. 
Other areas of research to pursue in this project involve looking at the different forms of 
LPA that may interact with osteoclasts.  In this project, 1-oleoyl lysophosphatidic acid was used, 
mainly because it is the most potent LPA analog characterized, and stimulates all five known 
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LPA receptors (van Corven 1992).  Cayman Chemicals Company manufactures a variety of LPA 
molecules with different side chains.  These modified versions of LPA include OMPT, 1-
octadectyl lysophosphatidic acid, and other varieties that only stimulate specific LPA receptors.  
Different cancer cell types may produce different forms of LPA, and examining the effect of 
these different LPA analogs on bone would also provide insight into the mechanism by which 
the primary cancer metastasizes to bone.   
The knowledge that LPAR2 is a major receptor involved in LPA-mediated actin sealing 
zone formation also has substantial implications.  Pharmaceutical isolation of pathways that are 
responsible for this increase in LPA levels may pioneer a new direction of benchtop research that 
has the potential to decrease the formation of secondary bone tumors.  For example, autotaxin is 
a protein induced by cancer cells that stimulates LPA production by circulating platelets in the 
blood (David 2010).  Perhaps rather than targeting the osteoclasts themselves, hindering 
autotaxin’s ability to induce these elevated LPA levels is a more effective means of preventing 
formation of the actin sealing zones that are necessary to osteoclast activity.  Interfering with the 
LPA-LPAR2 interaction prior to the actin sealing zone (and consequent resorption) increase may 
prove more practical than simply treating patients with a bisphosphonate (Figure 2d).   
Other labs have associated LPA with anti-apoptotic activity in leukemia cells (Kumar 
SA).  In one published case study, a cancer-free patient who had been treated long-term with 
bisphosphonates presented with giant osteoclasts that exhibited decreased resorptive function and 
a resistance to phagocytosis (Jain 2009).  Such results consequently increased the number of 
osteoclasts, which contrast my results that show the cells unable to form an actin ring when 
exposed first to Zometa and then LPA (Figure 4a).   These findings challenge researchers to 
further explore the mechanisms by which bisphosphonate activity is affected by LPA.  Such 
 19
research, in conjunction with my demonstration that LPA’s demonstrated anti-apoptotic 
mechanism overrides Zometa’s apoptotic activity, implies that clinicians need to treat LPA up-
regulation along with the cancer itself.   
 The siRNA knock-down of the LPAR2 gene also clarifies an important point in the 
understanding of how LPA affects the actin sealing zone.  As seen in Figure 8b, suppression of 
LPAR2 protein in the presence of LPA results in smaller actin sealing zones than those with a 
fully functional LPAR2 gene product.  However, osteoclasts with a knocked-down LPAR2 gene 
still formed an actin sealing zone, implying that although LPAR2 is important in sealing zone 
expansion, it is not solely responsible for the formation of the actin structure.  Figure 7a shows 
images in which osteoclasts were stained with an LPAR2-specific antibody (red), illustrating that 
LPAR2 is not present in the actin sealing zone itself (green), and LPAR2 is consequently not 
functioning to form the sealing zone.  I propose that there is an external signaling mechanism 
involved in this ring expansion, induced by LPA. 
The siRNA knock-down data strongly suggests that LPAR2 is primarily responsible for 
the expansion of the actin sealing zone.  However, the roles of LPAR1 and LPAR3 should not be 
ignored.  For example, LPAR1 was found to be the predominantly expressed LPA receptor in 
osteoclasts, and is speculated to be the receptor through which osteoblast-produced LPA reduces 
apoptosis of osteoclasts, extending the cell life (Lapierre 2008).   LPAR3 and other LPA 
receptors not yet characterized in osteoclasts may still be involved in the formation and turnover 
of actin structures.  This study focused on LPAR1, LPAR2, and LPAR3 because my lab had 
access to a pharmacological antagonist (Ki16425) and agonist (FAP12) for these receptors.  
When the FAP12 agonist cell treatment produced identical results to those generated with LPA 
treatment, experiments focused on the molecular aspects of LPAR2 expression.  That being said, 
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the potential impact of other LPA receptors cannot be overlooked, and requires further 
investigation. 
The results proving that adding LPA to cells increases the nuclear number leads to 
another area of conjecture.  One may speculate that the increased number of nuclei results from 
the LPA-induced fusion of cells.  From previous research conducted in the Lee lab, a correlation 
between actin sealing zone perimeter and nuclear number was established (McMichael 2009).  
Using this data, the actin sealing zone increase that was observed in my experiments fell in the 
normal ranges for the number of nuclei that were observed.  The mechanism by which LPA 
increases the degree of osteoclast fusion is uncertain.  The higher nuclear number may be a result 
of the LPA physiologically improving the osteoclasts’ ability to fuse, or the LPA-induced 
consequence of a decreased rate of apoptosis that increases the cells’ relative proximity and 
probability of fusing.  There may also be a motility effect that is enhanced by the LPA’s  
interaction with the cell, bringing the osteoclasts closer together.  The ramifications of LPA 
increasing the nuclear number and correlated bone resorptive capacity emphasize the importance 
of understanding the interaction of LPA with osteoclasts.  
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Figure 1 
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Figure 1: Actin sealing zone formation is essential to bone resorption by osteoclasts.       
(1a). As the osteoclast progresses from the resting state (top left) through to the resorption 
phase, the osteoclast polarizes and the actin sealing zone forms.  The release of Cathepsin K 
(Cat K) and HCl result in degradation of the bone matrix below the sealing zone area.  (1b).  
Top: Aerial view of osteoclast.  The red coloring indicates the actin sealing zone.  Bottom: 
Lateral view of the osteoclast.  (1c).  Bisphosphonates induce apoptosis in osteoclasts.  When 
administered, bisphosphonates adhere to the bone surface and are eliminated from the 
circulation, leaving most other somatic cells unaffected.  However, when osteoclasts resorb 
bone, they uptake the bisphosphonates along with the bone matrix.  The drugs are designed to 
induce apoptosis of the osteoclasts via an intracellular mechanism.  (Beauchamp 2002)  (1d).  
The chemical structure of lysophosphatidic acid (LPA). 
Side View
Top View
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Figure 2 
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Figure 2: LPA increases actin sealing zone size.  (2a).  The top left photo shows the actin sealing 
s 
ea 
lts 
zone of an untreated osteoclast in vehicle solution alone, while the photo on the right illustrates the 
sealing zone phenotype that results when osteoclasts are exposed to lysophosphatidic acid (LPA).  
The actin has been fluorescently stained, and can be distinguished as a bold ring structure.  Scale 
bar = 10 µm (2b). The graph on the left indicates expansion of the actin sealing zone in osteoclast
treated with LPA, relative to the vehicle control cells.   (2c).  The rightmost graph indicates that the 
nuclear number also increases upon addition of LPA in both subsets of RAW and MBM cells, 
trending with the larger sealing zone perimeter of the LPA-exposed osteoclasts.  (2d). On a 
synthetic bone medium, LPA addition results in a significant increase in the individual pit ar
resorbed, and in the total percent of the bone resorbed.  On an ivory medium, LPA addition resu
in a significant increase in the individual pit area resorbed, but shows no significant increase in the 
height of the resorption pit relative to the untreated vehicle control.   
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Figure 3 
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Figure 3: LPA and Zometa have contrary effects.  (3a). This figure illustrates the relative actin 
sealing zone sizes (bold ring structures), under conditions of LPA alone (left), Zometa only 
(middle) and LPA and Zometa added simultaneously (right).  Scale bar = 10 µm.  (3b).  This graph 
shows that adding LPA and Zometa to cells simultaneously produces actin sealing zones with a 
larger perimeter, comparable to the LPA-exposed phenotype.  (3c).  Adding LPA and Zometa to 
cells results in an increased nuclear number.  This nuclear number is statistically similar to the 
number of nuclei present in osteoclasts exposed to LPA alone. 
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Figure 4 
 
4a.   
  
63
 µ
m
 
96
 µ
m
 
80
 µ
m
 
 
4b.         4c.  
0
50
100
150
200
250
Contro l 2DZom-
1DLPA
2DLPA-
1DZom
pe
rim
et
er
 (µ
m
)
  
0
2
4
6
8
10
12
Contro l 2DZom-
1DLPA
2DLPA-
1DZom
N
uc
le
ar
 n
um
be
r
 
Untreated Control        2D Zom/1D LPA       2D LPA/1D Zom Untreated ol        2D Zom/1D LPA       2D LPA/1D Zom 
Se
al
in
g 
Zo
ne
 P
er
im
et
er
 (µ
m
) 
N
uc
le
ar
 N
um
be
r 
 
Figure 4: Pre-treatment with LPA makes Zometa ineffective. (4a) A time assay of osteoclast 
exposure to LPA and Zometa at different time points reveals that applying LPA to cells 24 hours 
prior to adding Zometa to the culture media makes Zometa ineffective.  Compared to the 
untreated control, cells treated with Zometa prior to LPA treatment (2D Zom-1D LPA) exhibited 
decreased actin ring size (or no ring formed at all), while cells treated with LPA first (2D LPA- 
1D Zom) displayed an actin sealing zone measuring approximately double the size of sealing 
zone of the untreated control.  (4b). The addition of LPA to osteoclasts 24 hours before Zometa 
results in a two-fold increase in the actin sealing zone.  (4c). The addition of LPA to osteoclasts 
24 hours before Zometa results in a higher nuclear number, corresponding to the increased size 
of the actin ring. 
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Figure 5 
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Figure 5: LPA Not Inhibited by LPAR1,3 Antagonist Ki16425.  (5a). The Ki16425 inhibitor, 
which inhibits LPAR1 and LPAR3 gene products, produces the same actin ring phenotype in 
cells as found with LPA. Scale bar = 10µm. (5b) and (5c). Osteoclasts exposed to both LPA and 
LPA + Ki16425 inhibitor result in an expanded actin ring perimeter, as well as an increased 
number of nuclei.  Since LPAR1 and LPAR3 were inhibited and the LPA-regulated sealing zone 
expansion was not hindered, it is not likely that LPAR1 or LPAR3 are significant mediators in 
the ring expansion mechanism.   
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Figure 6 
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Figure 6: LPAR2 Agonist FAP12 Mimics LPA Effects.  (6a). The FAP12 agonist, which is 
specific to LPAR2, produces the same actin ring phenotype in cells as found with LPA.  Both 
LPA and FAP12 result in an expanded actin ring relative to the untreated control.  Scale Bar = 
10µm (6b) and (6c). Osteoclasts exposed to both LPA and FAP12 agonist result in an 
expanded actin ring perimeter, as well as an increased number of nuclei.  The expanded actin 
sealing zone observed can be correlated with activation of LPAR2 as a result of this 
experiment.  (6d).  The LPA agonist FAP12 mimics LPA resorption patterns; addition of LPA 
or FAP12 to cells results in an increased resorption pit area relative to the untreated control. 
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Figure 7 
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Figure 8 
 
Figure 7: siRNA Suppression of LPAR2 diminishes LPA Effects   
 fluoresced red (middle).  Actin 
2-specifc 
As 
R 
 
(7a).  Osteoclasts were stained with LPAR2-specific antibodies, which
was stained with Phalloidin and fluoresced green (left).  The rightmost image confirms that LPAR2 is 
located throughout the osteoclast cell membrane, yet is not present in the actin ring structure.  
Scale bar = 10 µm. (7b). A competitive reverse-transcriptase PCR (RT-PCR) of the three LPAR
siRNAs shows that the siRNAs have effectively induced degradation of the cellular LPAR2 RNA 
products.  The relatively darker bands indicate that a higher concentration of each of the three siRN
was amplified in comparison to the LPAR2 gene product.  The control lane indicates that the initial 
amounts of internal standard (I.S.) and the LPAR2 gene product were approximately equal in the PC
mixture.  Such a control attributes any band discrepancies to the I.S. being selectively amplified during 
PCR, as a result of the knocked-down LPAR2 gene RNAs.  (7c). Western blot assays indicate that all 
three siRNAs knocked down the production of the LPAR2 protein.  siRNA 1 and siRNA 2 were most 
effective at suppressing LPAR2 expression.  A relatively constant amount of ß-actin protein, present in
all cells, ensures that the wells of the agarose gel were loaded consistently, and any change in the 
intensity of the protein bands can be explained by hindered protein production alone.   
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Figure 8 
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Figure 8: LPA is Responsible for Formation of Expanded Actin Sealing Zone.  (8a). Osteoclasts still 
  
ale bar = 
exhibit the expanded actin ring phenotype, even when transfected with a control (non-specific) siRNA.  
This observation confirms that the siRNAs are not involved in increasing the sealing zone perimeter. 
LPA interaction with LPAR2 is crucial to sealing zone expansion, since the cells transfected with 
LPAR2-specific siRNAs do not exhibit the larger sealing zone, even in the presence of LPA.  (8b).
Epifluorescent microscopy images compare the effects of control and LPAR2-specific siRNA 
transf ctions on actin ring structures.  Row 1 illustrates images at higher magnification (80x, sc
10µm), while Row 2 shows a wider field at a lower magnification (20x, scale bar = 56 µm). 
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ABBREVIATIONS SUMMARY 
 
atK – Cathepsin K 
leic Acid 
Eagle Medium 
 Receptor 
for Nuclear Factor κ B Ligand 
ription – Polymerase Chain Reaction 
 
 
C
DNA – Deoxyribonuc
DMEM – Dulbecco’s Modified 
LPA – Lysophosphatidic Acid 
LPAR– Lysophosphatidic Acid
MBM – Mouse Bone Marrow 
RANKL – Receptor Activator 
RNA – Ribonucleic Acid 
RT-PCR – Reverse Transc
siRNA – small interfering Ribonucleic Acid 
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